Antitumor activities of IL-12 and mechanisms of action

Chemical Immunology

Volumn 68, Issue , 1997, Pages 153-174

  Shurin, Michael R ^a   Esche, Clemens ^a   Péron, Jean Marie ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 12;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; DENDRITIC CELL; GENE THERAPY; NATURAL KILLER CELL; PRIORITY JOURNAL; REVIEW; TUMOR IMMUNITY;

EID: 0030955210     PISSN: 10150145     EISSN: None     Source Type: Journal    
DOI: 10.1159/000058690     Document Type: Review

References (103)

1. Trinchieri G: Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity. Annu Rev Immunol 1995;13:251-276.
2. Germann T, Rüde E: Interleukin-12. Int Arch Allergy Immunol 1995;108:103-112.
3. Stern AS, Magram J, Presky DH: Interleukin-12, an integral cytokine in the immune response. Life Sci 1996;58:639-654.
4. Kobayashi M, Fitz L, Ryan M, Hewick RM, Clark SC, Chan S, Loudon R, Sherman F, Perussia B, Trinchieri G: Identification and purification of natural killer cell stimulatory factor, a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989;170:827-845.
5. Lieberman MD, Sigal RK, Williams NN, Daly JM: Natural killer cell stimulatory factor augments natural killer cell and antibody-dependent tumoricidal response against colon carcinoma cell lines. J Surg Res 1991;50:410-415.
6. Chehimi J, Valiante NM, D'Andrea A, Rengaraju M, Rosado Z, Kobayashi M, Perussia B, Wolf SF, Starr SE, Trinchieri G: Enhancing effect of natural killer cell stimulatory factor (NKSF/ interleukin-12) on cell-mediated cytotoxicity against tumor-derived and virus-infected cells. Eur J Immunol 1993;23:1826-1830.
7. Rossi AR, Pericle F, Rasleigh S, Janiec J, Djeu JY: Lysis of neuroblastoma cell lines by human natural killer cells activated by interleukin-2 and interleukin-12. Blood 1994;83:1323-1328.
8. Mariani E, Tarozzi A, Meneghetti A, Tadolini M, Facchini A: Lytic activity of IL-2 and IL-12-stimulated NK cells against HOS osteosarcoma cell line. Boll Soc Ital Biol Sper 1996;72:21-27.
9. Soiffer RJ, Robertson MJ, Murray C, Cochran K, Ritz J: Interleukin-12 augments cytolytic activity of peripheral blood lymphocytes from patients with hematologic and solid malignancies. Blood 1993;82:2790-2796.
10. Andrews JV, Schoof DD, Bartagnolli MM, Peoples GE, Goedegebuure PS, Eberlein TJ: Immunomodulatory effects of interleukin-12 on human tumor-infiltrating lymphocytes. J Immunother 1993; 14:1-10.
11. Zeh HJ, Hurd S, Storkus WJ, Lotze MT: Interleukin-12 promotes the proliferation and cytolytic maturation of immune effectors: Implications for the immunotherapy of cancer. J Immunother 1993;14:155-161.
12. Zou JP, Yamamoto N, Fujii T, Takenaka H, Kobayashi M, Herrmann SH, Wolf SF, Fujiwara H, Hamaoka T: Systemic administration of rIL-2 induces complete tumor regression and protective immunity: Response is correlated with a striking reversal of suppressed IFN-gamma production by antitumor T cells. Int Immunol 1995;7:1135-1145.
13. + cytotoxic T lymphocytes from tumor-infiltrating lymphocytes. Jpn J Cancer Res 1995;86:135-139.
14. DeCesare SL, Michelini-Norris B, Blanchard DK, Barton DP, Cavanagh D, Roberts WS, Fiorica JV, Hoffmann MS, Djeu JY: Interleukin-12-mediated tumoricidal activity of patient lymphocytes in an autologous in vitro ovarian cancer assay system. Gynecol Oncol 1995;57:86-95.
15. Marana HR, Andrade JM, Silva JS: Natural killer cells and interleukin-12 in patients with advanced cervical cancer under neoadjuvant chemotherapy. Braz J Med Biol Res 1996;29:473-477.
16. Bigda J, Mysliwska J, Dziadziuszko R, Bigda J, Mysliwski A, Hellmann A: Interleukin-12 augments natural killer-cell mediated cytotoxicity in hairy cell leukemia. Leuk Lymphoma 1993; 10:121-125.
17. Hanagiri T, Takenoyama M, Yshimatsu T, Hirashima C, Yoshino I, Nakanishi K, Nagashima A, Nomoto K, Yasumoto K: Effects of interleukin-12 on in vitro culture with interleukin-2 of regional lymph node lymphocytes from lung cancer patients. Cancer Immunol Immunother 1996;43:87-93.
18. Gajewski TF, Renauld JC, Van Pel A, Boon T: Costimulation with B7-1, IL-6 and IL-12 is sufficient for primary generation of murine antitumor cytolytic T lymphocytes in vitro. J Immunol 1995;154: 5637-5648.
19. O'Toole M, Wolf S, O'Brien C, Hubbard B, Hermann S: Effect of in vivo IL-12 administration on murine tumour cell growth. J Immunol 1993;150:294A.
20. Brunda MJ, Luistro L, Hendrzak JA, Fountoulakis M, Garotta G, Gately MK: Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 1995;17:71-77.
21. Handel-Fernandez ME, Gheng X, Herbert LM, Lopez DM: Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. J Immunol 1997;158:280-286.
22. Brunda MJ, Luistro L, Rumennik L, Wright RB, Wigginton JM, Wiltrout RH, Hendrzak JA, Palleroni AV: Interleukin-12: Murine models of a potent antitumor agent. Ann NY Acad Sci 1996; 795:266-276.
23. Stine KC, Warren BA, Becton DL: Apoptosis induced by interleukin-12 measured by DNA electrophoresis and in situ end labeling in leukemia. Ann NY Acad Sci 1996;795:420-421.
24. Hiscox S, Hallett MB, Puntis MCA, Jiang WG: Inhibition of cancer cell motility and invasion by interleukin-12. Clin Exp Metastasis 1995;13:877-889.
25. Noguchi Y, Jungbluth A, Richards EC, Old L: Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci USA 1996;93:11798-11801.
26. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT: Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-1706.
27. Tannenbaum CS, Wicker N, Armstrong D, Tubbs R, Finke J, Bukowski RM, Hamilton TA: Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996;156:693-699.
28. Onishi T, Ohishi Y, Iuzuka N, Suzuki Y, Hosobe T, Nakajo H, Makino H, Saotome H: Study on anti-tumor effects of interleukin-12 for spontaneously arose murine renal cell carcinoma. Jpn J Urol 1996;87:1175-1182.
29. Mu J, Zou JP, Yamamoto N, Tsutsui T, Tai XG, Kobayashi M, Herrmann S, Fujiwara H, Hamaoka T: Administration of recombinant interleukin-12 prevents outgrowth of tumor cells metastasizing spontaneously to lung and lymph nodes. Cancer Res 1995;55:4404-4408.
30. Verbik DJ, Stinson WW, Brunda MJ, Kessinger A, Joshi SS: In vivo therapeutic effects of interleukin-12 against highly metastatic residual lymphoma. Clin Exp Metastasis 1996;14:219-229.
31. Okuno K, Jinnai H, Lee YS, Kaneda K, Yasutomi M: Interleukin-12 augments the liver-associated immunity and reduces liver metastases. Hepatogastroenterology 1996;43:1196-1202.
32. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12. J Immunol 1995;154:4333-4340.
33. + αβ T cells with potent cytotoxicity in the liver of mice via production of IL-12 from Kupffer cells. J Immunol 1996;156:2436-2442.
34. + αβ T cells activated by IL-12 as a major effector in inhibition of experimental tumor metastasis. J Immunol 1996;156:3366-3373.
35. Yu W, Yamamoto N, Takenaka H, Mu J, Tai XG, Zou JP, Ogawa M, Tsutsui T, Wijesuriya R, Yoshida R, Herrmann S, Fujiwara T: Molecular mechanisms underlying IFN-γ-mediated tumor growth inhibition induced during tumor immunotherapy with rIL-12. Int Immunol 1996;8:855-865.
36. Noguchi Y, Richards EC, Chen Y, Old LJ: Influence of IL-12 on p53 peptide vaccination against established Meth-A sarcoma. Proc Natl Acad Sci USA 1995;92:2219-2223.
37. Nishimura T, Watanabe K, Yahata T, Uede T, Saik, I, Herrmann SH, Kobayashi M, Habu S: The application of IL-12 to cytokine therapy for tumors. Ann NY Acad Sci 1996;795:375-378.
38. Martinotti A, Stoppacciaro A, Vagliani M, Melani C, Spreafico F, Wysocka M, Parmiani G, Trinchieri G, Colombo MP: CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995;25:137-146.
39. Rao JB, Chamberlain RS, Bronte V, Carroll MW, Irvine KR, Moss B, Rosenberg SA, Restifo NP: IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines: Enhancement by simultaneous B7-1 expression. J Immunol 1996;156:3357-3365.
40. Coughlin CM, Wysocka M, Kurzawa HL, Lee WM, Trinchieri G, Eck SL: B7-1 and interleukin-12 synergistically induce effective antitumor immunity. Cancer Res 1995;55:4980-4987.
41. Nishimura T, Watanabe K, Yahata T, Ushaku L, Ando K, Kimura M, Saiki I, Uede T, Habu S: Application of interleukin-12 to antitumor cytokine and gene therapy. Cancer Chemother Pharmacol 1996;38(suppl):27-34.
42. Vagtiani M, Rodolfo M, Cavallo F, Parenza M, Melani C, Parmiani G, Forni G, Colombo MP: Interleukin-12 potentiates the curative effect of a vaccine based on interleukin-2 transduced tumor cells. Cancer Res 1996;56:467-470.
43. Colombo MP, Vagliani M, Spreafico F, Parenza M, Chiodoni C, Melani C, Stoppacciaro A: Amount of interleukin-12 available at the tumor site is critical for tumor regression. Cancer Res 1996;56: 2531-2534.
44. Irvine KR, Rao JB, Rosenberg SA, Restifo NP: Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol 1996;156:238-245.
45. Leder GH, Oppenheim M, Rosenstein M, Lotze MT, Beger HG: Addition of interleukin-12 to low dose interleukin-2 treatment improves antitumor efficacy in vivo. Z Gastroenterol 1995;33:499-505.
46. 3 treatments to block induction of immunosuppressive granulocyte/macrophage progenitor cells. Cancer Immunol Immunother 1996;42:213-220.
47. Teicher BA, Ara G, Menon K, Schaub RG: In vivo studies with interleukin-12 alone and in combination with monocyte colony-stimulating factor and/or fractionated radiation treatment. Int J Cancer 1996;65:80-84.
48. Gately MK, Gubler U, Brunda MJ, Nadeau RR, Andersson TD, Lipman JM, Sarmiento U: Interleukin-12: A cytokine with therapeutic potential in oncology and infectious diseases. Ther Immunol 1994;1:187-196.
49. Brunda MJ, Luistro L, Rumennik L, Wright RB, Dvorozniak M, Aglione A, Wigginton JM, Wiltrout RH, Hendrzak JA, Palleroni AV: Antitumor activity of interleukin-12 in preclinical models. Cancer Chemother Pharmacol 1996;38(suppl):16-21.
50. Lotze MT, Zitvogel L, Campbell R, Robbins PD, Elder E, Haluszczak C, Martin D, Whiteside TL, Storkus WJ, Tahara H: Cytokine gene therapy of cancer using interleukin-12: Murine and clinical trials. Ann NY Acad Sci 1996;795:440-454.
51. Lamont AG, Adorini L: IL-12: A key cytokine in immune regulation. Immunol Today 1996;17: 214-217.
52. Del Vecchio M, Mortarini R, Rimassa L, Fowst C, Anichini A, Parmiani G, Cascinelli N, Bajetta E: Preliminary experience with rHu IL-12 in the treatment of metastatic melanoma. J Clin Oncol 1996;14:1748-1752.
53. Marshall E: Cancer trial of interleukin-12 halted. Science 1995;268:1555.
54. Tahara H, Zitvogel L, Storkus WJ, Elder EM, Kinzler D, Whiteside TL, Robbins PD, Lotze MT: Antitumor effects in patients with melanoma, head and neck carcinoma and breast cancer in Phase I/II clinical trials of interleukin-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Proc ASCO 1997, in press.
55. Tahara H, Zitvogel L, Storkus WJ, Robbins PD, Lotze MT: Murine models of cancer cytokine gene therapy using interleukin-12. Ann NY Acad Sci 1996;795:275-283.
56. Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT: Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy. J Surg Res 1995;58:218-226.
57. Zitvogel L, Mayordomo JI, Tjandrawan T, DeLeo AB, Clarke MR, Lotze MT: Therapy of murine tumors with tumor peptide-pulsed dendritic cells: Dependence on T cells, B7 costimulation and T helper cell 1-associated cytokines. J Exp Med 1996;183:87-97.
58. Tahara H, Zeh H Jr, Storkus WJ, Pappo J, Watkins SC, Gubler U, Wolf SF, Robbins PD, Lotze MT: Fibroblasts genetically engineered to secrete interleukin-12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994;54:182-189.
59. Obana S, Miyazawa H, Hara E, Tamura T, Nariuchi M, Fujimoto S, Yamamoto H: Induction of anti-tumor immunity by mouse tumor cells transfected with mouse interleukin-12 gene. Jpn J Med Sci Biol 1995;48:221-236.
60. Rodolfo M, Zilocchi C, Melani C, Cappetti B, Arioli I, Parmiani G, Colombo MP: Immunotherapy of experimental me;tastases by vaccination with interleukin gene-transduced tumor cell vaccines. J Immunol 1996;157:5536-5542.
61. Meko JB, Tsung K, Norton JA: Cytokine production and anti-tumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12. Surgery 1996;120:274-282.
62. 62a Chen PW, Geer DC, Podack ER, Ksander BR: Tumor cells transfected with B7-1 and interleukin-12 cDNA induce protective immunity. Ann NY Acad Sci 1996;795:325-327.
63. 62b Rakhmilevich AL, Turner J, Ford MJ, McCabe D, Sun WH, Sondel PM, Grota K, Yang NS: Gene gun-mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996;93:6291-6296.
64. Bramson J, Hitt M, Gallichan WS, Rosenthal KL, Gauldie J, Graham FL: Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: In vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996;7:333-342.
65. Caruso M, Nguyen KP, Kwong YL, Bisong X, Kosai KI, Finegold M, Woo S, Chen SH: Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996;93:11302-11306.
66. Tahara H, Zitvogel L, Storkus WJ, Zeh H, McKinney HG, Schreiber TG, Gubler U, Robbins PD, Lotze MT: Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154:6466-6474.
67. Sotomayor EM, Cheng XF, Fu YX, Hawkins A, Calderon-Higginson C, Lopez DM: Impaired activation of tumoricidal function in macrophages from mammary tumor bearers: The role of IFN-γ. Int J Oncol 1993;3:719-722.
68. Ghosh P, Komschlies KL, Cippitelli M, Longo DL, Subleski J, Ye J, Sica A, Young H, Wiltrout RH, Ochoa AC: Gradual loss of T-helper 1 populations in spleen of mice during progressive tumor growth. J Natl Cancer Inst 1995;87:1478-1483.
69. Rook AH, Kubin M, Fox FE, Niu Z, Cassin M, Vowels BR, Gottlieb SL, Vonderhuid EC, Lessin SR, Trinchieri G: The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann NY Acad Sci 1996;795:310-318.
70. Hegde SP, Bright JJ, Kausalya S, Khar A: AK-5 tumor-induced expression of interleukin-12: Role of IL-12 in NK-mediated AK-5 regression. Cell Immunol 1995;162:241-247.
71. Brunda MJ, Luistro L, Warrier RR, Wright RB, Hubbard BR, Murphy M, Wolf SF, Gately MK: Antitumor effect and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993;178:1223-1230.
72. Nastala CL, McKinney TJ, Edington HD, Tahara H, Storkus WJ, Lotze MT: Interleukin-12 induces specific antitumor immunity in animals bearing established subcutaneous murine sarcoma. Surg Forum 1994;45:492-494.
73. Brunda MJ, Gately MK: Interleukin-12: Potential role in cancer therapy; in DeVita VT, Hellman S, Rosenberg SA (eds): Important Adv Oncol 1995. Philadelphia, Lippincott, 1995, pp 3-18.
74. Ghosh P, Sica A, Young HA, Ye J, Franco JL, Wiltrout RH, Longo DL, Rice NR, Komschlies KL: Alterations in NFκB/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 1994;54:2969-2972.
75. Fujiwara H, Hamaoka T: Antitumor and antimetastatic effects of interleukin-12. Cancer Chemother Pharmacol 1996;38(suppl):22-26.
76. Wigginton JM, Kuhns DB, Back TC, Brunda M, Wiltrout RH, Cox GW: Interleukin-12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: Implications for the antitumor activity of interleukin-12 and/or interleukin-2. Cancer Res 1996;56:1131-1136.
77. Mantovani A: Tumor-associated macrophages in neoplastic progression: A paradigm for the in vivo function of chemokines. Lab Invest 1994;71:5-16.
78. Cui S, Reichner JS, Mateo RB, Albina JE: Activated murine macrophages induce apoptosis in tumor cells through nitric oxide-dependent or -independent mechanisms. Cancer Res 1994;54: 2462-2467.
79. Sagar SM, Singh G, Hodson DI, Whitton AC: Nitric oxide and anti-cancer therapy. Cancer Treat Rev 1995;21:159-181.
80. Dighe AS, Richards E, Old LS, Schreiber RD: Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-gamma receptors. Immunity 1994;1:447-456.
81. Howard B, Burrascano M, McCallister T, Chong K, Gangavalli R, Severinsson L, Jolly DJ, Darrow T, Vervaert C, Abdel-Wahab Z: Retrovirus-mediated gene transfer of the human gamma-IFN gene: A therapy tor cancer. Ann NY Acad Sci 1994;716:167-187.
82. Lu Y, Boss JM, Hu SX, Xu HJ, Blanck G: Apoptosis-independent retinoblastoma protein rescue of HLA class II messenger RNA IFN-gamma inducibility in non-small cell lung carcinoma cells. Lack of surface class II expression associated with a specific defect in HLA-DRA induction. J Immunol 1996;156:2495-2502.
83. Vegh Z, Wang P, Vanky F, Klein E: Selectively down-regulated expression of major histocompatibility complex class I alleles in human solid tumor. Cancer Res 1993;53(suppl):2416-420.
84. Ozaki Y, Edelstein MP, Duch DS: Induction of indoleamme 2,3-dioxygenase: A mechanism of the antitumor activity of interferon-γ. Proc Natl Acad Sci USA 1988;85:1242.
85. Burke F, Balkwill FR: Cytokines in animal models of cancer. Biotherapy 1996;8:229-241.
86. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkmann J: Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995;87:581-586.
87. Majewski S, Marczak M, Szmurlo A, Jablonska S, Bollag W: Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 1996;106:1114-1118.
88. Mori K, Fujimot-Ouchi K, Ishikawa T, Sekiguchi F, Ishitsuka H, Tanaka Y: Murine interleukin-12 prevents the development of cancer cachexia in a murine model. Int J Cancer 1996;67:849-855.
89. Trinchieri G: Interleukin-12: A cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood 1994; 84:4008-4027.
90. Shurin MR: Dendritic cells presenting tumor antigen. Cancer Immunol Immunother 1996;43: 158-164.
91. Bianchi R, Grohmann U, Belladonna ML, Silla S, Fallarino F, Ayroldi E, Fioretti MC, Puccetti P: IL-12 is both required and sufficient for initiating T cell reactivity to a class I-restricted tumor peptide (P815AB) following transfer of P815AB-pulsed dendritic cells. J Immunol 1996;157:1589-1597.
92. Zitvogel L, Tahara H, Robbins PD, Storkus WJ, Clarke MR, Nalesnik MA, Lotze MT: Cancer immunotherapy of established tumors with IL-12. Effective delivery by genetically engineered fibroblasts. J Immunol 1995;155:1393-1403.
93. Zitvogel L, Couderc B, Mayordomo JL, Robbins P, Lotze MT, Storkus WJ: IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo. Ann NY Acad Sci 1996;795: 284-293.
94. Fallarino F, Uyttenhove C, Boon T, Gajewski T: Endogenous IL-12 is necessary for rejection of P815 tumor variants in vivo. J Immunol 1996;156:1095-1100.
95. Scheicher C, Mehlig M, Dienes HP, Reske K: Uptake of micropartide-absorbed protein antigen by hone-marrow derived dendritic cells results in up-regulation of interleukin-1α and interleukin-12 p40/p35 and triggers prolonged, efficient antigen presentation. Eur J Immunol 1995;25:1566-1572.
96. + T cells. J Immunol 1995;154:5071-5079.
97. Heufler C, Koch F, Stanzl U, Topar G, Wysocka M, Trinchieri G, Enk A, Steinmann RM, Romani N, Schuler G: Interleukin-12 is produced by dendritic cells and mediates T helper 1 development as well as interferon-γ production by T helper 1 cells. Eur J Immunol 1996;26:659-668.
98. Cohen J: IL-12 deaths: Explanation and a puzzle. Science 1995;270:908.
99. Fujiwara H, Clark SC, Hamaoka T: Cellular and molecular mechanisms underlying IL-12-induced tumor regression. Ann NY Acad Sci 1996;795:294-309.
100. Wysocka M, Coughlin CM, Kurzawa HL, Trinchieri G, Eck SL, Lee WMF: Mechanism of the induction of anti-tumor immunity by B7.1 and interleukin-12. Ann NY Acad Sci 1996;795:429-433.
101. Zitvogel L, Robbins PD, Storkus WJ, Clarke MR, Maeurer MJ, Campbell RL, Davis CG, Tahara H, Schreiber RD, Lotze MT: Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur J Immunol 1996;26:1335-1341.
102. Stern LL, Tarby CM, Tamborini B, Truitt GA: Preclinical development of IL-12 as an anticancer drug: Comparison to IL-12. Proc Am Assoc Cancer Res 1994;35:520A.
103. Wigginton JM, Komschlies KL, Back TC, Franco JL, Brunda MJ, Wiltrout RH: Administration of interleukin-12 pulse interleukin-2 and the rapid and complete eradication of murine renal carcinoma. J Natl Cancer lnst 1996;88:38-43.